Paul Van Damme
Managing Director

Paul joined Wildlaw Capital Markets in 2011 as a Managing Director with a focus on providing CFO-level financial and strategic services to public companies in order to provide a full service solution to our clients.

Previously, Paul served in senior financial roles for several public companies in both the United States and Canada. He held a number of increasingly responsible positions while at Canada Systems Group between 1983 and 1991, including a line management role, culminating in his appointment as Chief Financial Officer in 1988. In 1991, Paul joined Laidlaw Inc. and helped implement their expansion into Europe. After a period as Chief Financial Officer of a start-up wireless telecommunications company, he joined a private biotech company and helped raise venture financing to expand their product portfolio. Paul later joined Allelix Pharmaceuticals Inc. and participated in the sale of the company to NPS Pharmaceuticals, Inc. of Salt Lake City. Most recently, he was the CFO of Bradmer Pharmaceuticals Inc.

Paul received his undergraduate degree (B.Comm.) from the University of Toronto and his MBA from the Rotman School of Management. He is a Chartered Accountant and articled with PricewaterhouseCoopers where he served as Audit Manager in London, England and Toronto, Canada. He’s currently on the Board of Directors at Quest PharmaTech Inc. and at Insception Biosciences Inc.

P: 416-847-6905